Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Seventeen cancer drugs have been added to the interaction checker

Wednesday 01 June 2022

Apalutamide, atezolizumab, binimetinib, cafilzomib, cyclophosphamide, dactinomycin, encorafenib, eribulin, etoposide, letrozole, talazoparib, tamoxifen, tegafur/gimeracil/oteracil, topotecan, trifluridine/tipiracil, vinblastine and vincristine are all now listed in the interaction checker as cancer drugs and interactions can be found with all comedications.

  • Apalutamide (Erleada®) is a non-steroidal antiandrogen and is indicated for the treatment of prostate cancer.
  • Atezolizumab (Tecentriq®) is a monoclonal antibody and is indicated for the treatment of non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma and breast cancer.
  • Binimetinib (Mektovi®) is a MAP2K tyrosine kinase inhibitor and is indicated for the treatment of melanoma.
  • Carfilzomib (Kyproliz®) is a selective proteasome inhibitor and is indicated for the treatment of multiple myeloma.
  • Cyclophosphamide (Cytoxan®, Neosar®) is an alkylating agent and is indicated for the treatment of multiple myeloma, haematological malignancies, breast cancer, ovarian cancer and neuroblastoma.
  • Dactinomycin (Cosmegen Lyovac®, Actinomycin D) is an anti-tumour antibiotic and is indicated for the treatment of testicular cancer, ovarian cancer, melanomas and sarcomas.
  • Encorafenib (Braftovi®) is a BRAF inhibitor and is indicated for the treatment of melanoma and colorectal cancers.
  • Erlubin (Halaven®) is a mitotic inhibitor and is indicated for the treatment of breast cancer and sarcomas.
  • Etoposide (Etopophos®, Toposar®, Vepesid®) is a topo-isomerase inhibitor and is indicated for the treatment of lung cancer, ovarian cancer, testicular cancer, haematological malignancies and neuroblastoma.
  • Letrozole (Femara®) is an aromatase inhibitor and is indicated for the treatment of hormonally-responsive breast cancer.
  • Talazoparib (Talzenna®) is a PARP inhibitor and is indicated for the treatment of advanced breast cancer with BCRA mutations.
  • Tamoxifen (Nolvadex®, Soltamox®) is a selective estrogen receptor modulator and is indicated for the treatment and prevention of breast cancer.
  • Tegafur/Gimeracil/Oteracil (Teysuno®) is an anti-metabolite and is indicated for the treatment of gastrointestinal cancers.
  • Topotecan (Hycamtin®, Potactasol®) is a topo-isomerase inhibitor and is indicated for the treatment of ovarian cancer and small cell lung cancer.
  • Trifluridine/Tipiracil (Lonsurf®) is an anti-metabolite and is indicated for the treatment of gastrointestinal cancers.
  • Vinblastine (Velban®, Velbe®, Alkaban-AQ) is a vinca alkaloid and is indicated for the treatment of breast cancer and testicular cancers.
  • Vincristine (Mariqbo®, Oncovin®, Vincasar PFS® and Vincrex®) is a vinca alkaloid and is indicated for the treatment of breast cancer, haematological malignancies, neuroblastoma, small cell lung cancer and sarcomas.
ENDORSED BY
Bopa Esop gro%c3%9f %28resized%29